Opinion statement
The risks of cardiovascular disease, cerebrovascular disease, peripheral artery disease, and end-stage renal disease are linearly related to systolic blood pressure. As the population ages and the prevalence of high blood pressure increases, the implementation of population-based strategies will be essential to reduce the burden of hypertension-related diseases. Reduction and control of elevated blood pressure can effectively slow the progression of end-stage renal disease, cerebrovascular disease, peripheral vascular disease, and cardiovascular disease. The strategies for population-based hypertension control are implemented through an increased awareness of the newest guidelines. In the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the strategies include lifestyle modification and antihypertensive medication. Although specific blood pressure levels determine antihypertensive medications, lifestyle modifications are advised for all segments of the population and for all blood pressure levels. In particular, lifestyle modification is the recommended intervention for the “prehypertension” category and is encouraged for individuals with normal blood pressure. Also, strategies for lifestyle modifications are part of the treatment strategies for stage 1 and stage 2 hypertension categories in conjunction with antihypertensive medications. The major lifestyle modifications to reduce and manage blood pressure include weight management, incorporation of specific diet plans, dietary sodium reduction, physical activity, and moderation of alcoholic consumption. The implementation and commitment to these strategies can effectively and significantly reduce blood pressure levels, and subsequent hypertension-related disease risks in the population.
Similar content being viewed by others
References and Recommended Reading
Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003, 289:2560–2572. This is the summary of the JNC 7 reports and represents an excellent review of the guidelines. The document is an important clinical reference.
Sacks FM, Svetkey LP, Vollmer WM, et al.: Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium Collaboration Research Group. N Engl J Med 2001, 344:3–10.
Effects of weight loss and sodium reduction on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group [no authors listed]. Arch Intern Med 1997, 157:657–667.
Ho J, Whelton PK, Appel LJ, et al.: Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2004, 35:444–449.
Wolk R, Shamsuzzaman AS, Somers VK: Obesity, sleep apnea, and hypertension. Hypertension 2003, 42:1067–1074.
Reaven GM: Importance of identifying the overweight patient who will benefit the most by losing weight. Ann Intern Med 2003, 138:1420–1423.
Sacks FM, Svetkey LP, Vollmer WM, et al.: Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001, 135:1019–1028.
Bray GA Vollmer VM, Sacks FM, et al.: A further sub-group analysis of the effects of the DASH diet and three sodium levels on blood pressure: results of the DASH-Sodium Trial. Am J Cardiol 2004, 94:222–227.
Svetkey LP, Simons-Morton DG, Proschan MA, et al.: Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control. J Clin Hypertens 2004, 6:373–381.
Appel LJ, Champagne CM, Harsha DW, et al.: Effects of comprehensive lifestyle modification on blood pressure control in main results of the PREMIER clinical trial. JAMA 2003, 289:2083–2093.
Stamler J: The INTERSALT Study: background, methods, findings, and implications. Am J Clin Nutr 1997, 65:626S-642S.
Forrester T: Historic and early life origins of hypertension in Africans. J Nutr 2004, 134:211–216.
Ergul A: Hypertension in black patients: an emerging role of the endothelium system in salt sensitive hypertension. Hypertension 2000, 36:62–67.
Tobian L: Dietary sodium chloride and potassium have effects on the pathophysiology of hypertension in humans and animals. Am J Clin Nutr 1997, 65:606S-611S.
Kotchen TA, Kotchen JM: Dietary sodium and blood pressure: interactions with other nutrients. Am J Clin Nutr 1997, 65:708S-711S.
Cutler JA: The effects of reducing sodium and increasing potassium intake for control of hypertension and improving health. Clin Exp Hypertens 1999, 21:769–783.
Zoccali C, Mallamaci T: The salt epidemic: old and new concerns. Nutr Metab Cardiovasc Dis 2000, 10:168–171.
Kelley GA, Kelley KS: Progressive resistance exercise and resting blood pressure: a meta-analysis of randomized controlled trails. Hypertension 2000, 35:838–843.
Whelton SP, Chin A, Xin X, et al.: Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002, 136:493–503.
Kokkinos PF, Papademetriou V: Exercise and hypertension. Coron Artery Dis 2000, 11:99–102.
Reisin F: Nonpharmacologic approaches to hypertension. Weight, sodium, alcohol, exercise and tobacco considerations. Med Clin North Am 1997, 81:1289–1303.
Xin X, He J, Frontini MG, et al.: Effects of alcohol reduction on blood pressure. A meta-analysis of randomized controlled trials. Ann Intern Med 2001, 38:1112–1117.
Beilin L, Puddey IB, Burke V: Alcohol and hypertension—kill or cure? J Hum Hypertens 1996, 10(suppl 2):S1-S5.
Lip GY, Beevers DG: Alcohol and cardiovascular disease—more than one paradox to consider. Alcohol and hypertension-does it matter? (no!). J Cardiovasc Risk 2003, 10:11–14.
Lewis EJ, Hunsucker LG, Bain RP et al.: The effect of angiotensin-converting enzyme inhibitor on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456–1462.
Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.
Lewis EJ, Hansucker LG, Clark WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.
Cushman WC, Ford CE, Cutler JA, et al.: Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002, 4:393–404.
Black HR, Elliott WJ, Neaton JD, et al.: Baseline characteristics and elderly blood pressure control in the CONVINCE trial. Hypertension 2001, 37:12–18.
Miller ER, Erlinger TR Young DR, et al.: Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). Hypertension 2002, 40:612–618.
Conlin PR, Erlinger TR Bohannon A, et al.: The DASH diet enhances the blood pressure response to losartan in hypertensive patients. Am J Hypertens 2003, 16:337–342.
Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 50%. BMJ 2003, 326:1419–1423.
Franco OH, Bonneux L, de Laet C, et al.: The Polymeal: a more natural, safer, and probably tastier (than the Polypill) strategy to reduce cardiovascular disease by more than 75%. BMJ 2004, 329:1447–1450.
Franklin BA, Kahn JK, Gordon NF, et al.: A cardioprotective “polypill”? Independent and additive benefits of lifestyle modification. Am J Cardiol 2004, 94:162–166.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lackland, D.T. Population strategies to treat hypertension. Curr Treat Options Cardio Med 7, 253–258 (2005). https://doi.org/10.1007/s11936-005-0036-9
Issue Date:
DOI: https://doi.org/10.1007/s11936-005-0036-9